MedElevator
Войти в исследования Diabetes, obesity, and cardiometabolic CARE · 2026
Acceptability and Feasibility of a Primary Care Hypoglycemia Prevention Program: A Pilot Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pilla Scott J, Bugayong Marielle T, Moreno Jose Amezcua, Abusamaan Mohammed S, Saha Somnath, Snyder Claire, McCoy Rozalina G, Ratzki-Leewing Alexandria, Kahkoska Anna R, Schrock Susan H, Mathioudakis Nestoras N, Maruthur Nisa M
Аннотация
OBJECTIVE: Hypoglycemia, a major cause of morbidity for people with diabetes, is underrecognized in primary care, leading to underuse of risk mitigation strategies. This study reports the development and acceptability/feasibility testing of the Hypoglycemia Prevention Program (HPP), an electronic health record-integrated toolkit for primary care.
RESEARCH DESIGN AND METHODS: The HPP was developed through stakeholder engagement and included a pre-visit hypoglycemia history survey, primary care provider (PCP) hypoglycemia toolkit, and patient self-management handout. The HPP pilot study was a pre-post clinical trial at one primary care practice. Participants were adults with diabetes treated with insulin or sulfonylureas, their PCPs, and clinic staff. The primary outcome was acceptability; exploratory outcomes included pre- to postintervention change in PCP hypoglycemia prevention actions, self-reported hypoglycemia, and optional blinded 10-day continuous glucose monitoring (CGM).
RESULTS: The intervention was completed by 31 of 35 enrolled patients with diabetes (89%) for whom it triggered frequent hypoglycemia alerts. The intervention was rated acceptable or completely acceptable by 87% of patients and 100% of participating PCPs (n = 12) and clinic staff (n = 5). PCPs increased indicated glucagon prescribing from pre- to postintervention (0% preintervention to 32% postintervention, P = 0.003); there were small increases in CGM initiation and deintensification of hypoglycemia-causing medications. Self-reported and CGM-detected hypoglycemia decreased from pre- to postintervention, although with incomplete ascertainment and low CGM participation (n = 11).
CONCLUSIONS: A hypoglycemia prevention program designed for primary care is feasible to implement and acceptable to clinical and patient stakeholders, with evidence of improved hypoglycemia prevention efforts. Further efficacy evaluation is needed.
RESEARCH DESIGN AND METHODS: The HPP was developed through stakeholder engagement and included a pre-visit hypoglycemia history survey, primary care provider (PCP) hypoglycemia toolkit, and patient self-management handout. The HPP pilot study was a pre-post clinical trial at one primary care practice. Participants were adults with diabetes treated with insulin or sulfonylureas, their PCPs, and clinic staff. The primary outcome was acceptability; exploratory outcomes included pre- to postintervention change in PCP hypoglycemia prevention actions, self-reported hypoglycemia, and optional blinded 10-day continuous glucose monitoring (CGM).
RESULTS: The intervention was completed by 31 of 35 enrolled patients with diabetes (89%) for whom it triggered frequent hypoglycemia alerts. The intervention was rated acceptable or completely acceptable by 87% of patients and 100% of participating PCPs (n = 12) and clinic staff (n = 5). PCPs increased indicated glucagon prescribing from pre- to postintervention (0% preintervention to 32% postintervention, P = 0.003); there were small increases in CGM initiation and deintensification of hypoglycemia-causing medications. Self-reported and CGM-detected hypoglycemia decreased from pre- to postintervention, although with incomplete ascertainment and low CGM participation (n = 11).
CONCLUSIONS: A hypoglycemia prevention program designed for primary care is feasible to implement and acceptable to clinical and patient stakeholders, with evidence of improved hypoglycemia prevention efforts. Further efficacy evaluation is needed.